Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$122.18

-0.44 (-0.36%)

07:02
10/12/18
10/12
07:02
10/12/18
07:02

Sarepta initiated with an Outperform at Bernstein

Bernstein analyst Vincent Chen initiated Sarepta with an Outperform rating and $170 price target. In a research note to investors, Chen says that a "confluence" of factors make DMD a best case scenario, and very high value, for gene therapy, and while he says manufacturing is not easy, he does not think it will be a problem. Chen says he is "fairly" confident Sarepta can succeed after a deep dive into gene therapy manufacturing.

SRPT Sarepta
$122.18

-0.44 (-0.36%)

10/04/18
JANY
10/04/18
NO CHANGE
Target $200
JANY
Buy
Sarepta micro-dystrophin gene therapy update continues to impress, says Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong believes the three-month muscle biopsy data from the fourth patient and the functional results from all four patients that Sarepta reported at the Annual Congress of the World Muscle Society provide "strong" additional evidence to support a favorable clinical profile of the micro-dystrophin gene therapy program. The analyst notes that management has requested a meeting with the FDA and he continues to expect the agency to be supportive for an expedited regulatory pathway. Upon FDA feedback, patient dosing in the pivotal study could begin in Q4 of 2018/Q1 of 2019, he contends. Additionally, Zhong expects the initial data from the LGMD2E gene therapy program to be positive, based on a readthrough from the micro-dystrophin program. He reiterates a Buy rating and $200 fair value estimate on the shares.
10/04/18
NEED
10/04/18
NO CHANGE
NEED
Needham impressed with Sarepta micro-dystrophin gene therapy data
Needham analyst Chad Messer reiterated a Buy rating and $196 price target after updated data from Sarepta's micro-dystrophin gene therapy program was presented at the World Muscle Society Congress. The data indicated that all four patients showed "impressive improvements on multiple functional measures," and Messer noted that Sarepta has already requested an FDA meeting and expects to initiate a pivotal study by the end of this year.
10/04/18
FBCO
10/04/18
NO CHANGE
Target $189
FBCO
Outperform
Sarepta price target raised to $189 from $178 at Credit Suisse
10/04/18
PIPR
10/04/18
NO CHANGE
Target $189
PIPR
Overweight
Sarepta price target raised to $189 from $168 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics to $189 after the company presented new Phase I/II microdystrophin gene therapy data for a four Duchenne muscular dystrophy boy and updated data for three boys. The analyst views the data for the fourth boy as "robust"and says microdystrophin is safe with durable gene expression. He believes micro-dystrophin geneRx could address up to 70% of DMD boys and gain accelerated approval in 2020. Tenthoff reiterates an Overweight rating on shares of Sarepta.

TODAY'S FREE FLY STORIES

ARRS

Arris

$31.65

0.025 (0.08%)

07:11
02/21/19
02/21
07:11
02/21/19
07:11
Earnings
Arris reports preliminary Q4 adjusted EPS 76c, consensus 75c »

Reports Q4 preliminary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$17.64

-0.25 (-1.40%)

07:10
02/21/19
02/21
07:10
02/21/19
07:10
Hot Stocks
Wendy's approves new $225M share repurchase program »

At the end of 2018, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Mar

QEP

QEP Resources

$8.19

-0.08 (-0.97%)

07:10
02/21/19
02/21
07:10
02/21/19
07:10
Recommendations
QEP Resources analyst commentary  »

Elliott may push for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

BRC

Brady

$47.35

0.59 (1.26%)

07:10
02/21/19
02/21
07:10
02/21/19
07:10
Earnings
Brady reports Q2 EPS 55c, consensus 52c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 28

    Mar

AVB

AvalonBay

$194.14

-2.37 (-1.21%)

07:09
02/21/19
02/21
07:09
02/21/19
07:09
Downgrade
AvalonBay rating change  »

Citi downgrades AvalonBay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

ARD

Ardagh Group

$12.98

0.32 (2.53%)

07:09
02/21/19
02/21
07:09
02/21/19
07:09
Hot Stocks
Breaking Hot Stocks news story on Ardagh Group »

Ardagh Group sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

ARD

Ardagh Group

$12.98

0.32 (2.53%)

07:08
02/21/19
02/21
07:08
02/21/19
07:08
Earnings
Ardagh Group sees FY19 adjusted EPS $1.60-$1.75, consensus $1.76 »

2019 outlook: Full year…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

IRT

Independence Realty Trust

$10.71

-0.01 (-0.09%)

07:08
02/21/19
02/21
07:08
02/21/19
07:08
Earnings
Independence Realty sees FY19 EPS 76c-80c, may not compare to consensus 24c 

Sees FY19 CFFO 74c-78c.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

WEN

Wendy's

$17.64

-0.25 (-1.40%)

07:08
02/21/19
02/21
07:08
02/21/19
07:08
Earnings
Wendy's sees FY20 global systemwide sales of approximately $11.5B »

Sees FY20 free cash flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Mar

ALB

Albemarle

$82.82

-0.305 (-0.37%)

07:08
02/21/19
02/21
07:08
02/21/19
07:08
Recommendations
Albemarle analyst commentary  »

Oppenheimer says remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 27

    Feb

BDC

Belden

$63.83

7.19 (12.69%)

07:08
02/21/19
02/21
07:08
02/21/19
07:08
Recommendations
Belden analyst commentary  »

Belden price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    May

  • 14

    May

  • 15

    May

MCRN

Milacron

$14.78

0.13 (0.89%)

07:08
02/21/19
02/21
07:08
02/21/19
07:08
Earnings
Milacron sees FY19 pro forma sales growth 0%-1%, consensus $1.28B »

In line with current…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

ARD

Ardagh Group

$12.98

0.32 (2.53%)

07:07
02/21/19
02/21
07:07
02/21/19
07:07
Earnings
Ardagh Group reports Q4 adjusted EPS 33c, consensus 28c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GIL

Gildan Activewear

$34.17

-0.17 (-0.50%)

07:07
02/21/19
02/21
07:07
02/21/19
07:07
Earnings
Breaking Earnings news story on Gildan Activewear »

Gildan Activewear sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

IRT

Independence Realty Trust

$10.71

-0.01 (-0.09%)

07:07
02/21/19
02/21
07:07
02/21/19
07:07
Earnings
Independence Realty Trust reports Q4 EPS 16c, consensus 5c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

WEN

Wendy's

$17.64

-0.25 (-1.40%)

07:07
02/21/19
02/21
07:07
02/21/19
07:07
Earnings
Wendy's sees FY19 adjusted EPS growth of 3.5%-7%, consensus 66c »

Sees FY19 global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Mar

BTX

BioTime

$1.16

-0.11 (-8.66%)

07:07
02/21/19
02/21
07:07
02/21/19
07:07
Initiation
BioTime initiated  »

BioTime initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 07

    Mar

GIL

Gildan Activewear

$34.17

-0.17 (-0.50%)

07:06
02/21/19
02/21
07:06
02/21/19
07:06
Earnings
Breaking Earnings news story on Gildan Activewear »

Gildan Activewear sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

FARO

Faro Technologies

$43.78

-4.16 (-8.68%)

07:06
02/21/19
02/21
07:06
02/21/19
07:06
Downgrade
Faro Technologies rating change  »

Faro Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCOI

Cogent

$49.78

-0.495 (-0.98%)

07:06
02/21/19
02/21
07:06
02/21/19
07:06
Hot Stocks
Cogent raises quarterly dividend to 58c from 56c per share »

Payable on March 29 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 11

    Mar

  • 11

    Mar

  • 13

    Mar

NCLH

Norwegian Cruise Line

$53.72

0.33 (0.62%)

07:06
02/21/19
02/21
07:06
02/21/19
07:06
Earnings
Breaking Earnings news story on Norwegian Cruise Line »

Norwegian Cruise Line…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 03

    Mar

  • 28

    May

NCLH

Norwegian Cruise Line

$53.72

0.33 (0.62%)

07:06
02/21/19
02/21
07:06
02/21/19
07:06
Earnings
Norwegian Cruise Line sees FY19 adjusted EPS $5.20-$5.30, consensus $5.15 »

As of December 31, 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 03

    Mar

  • 28

    May

CCOI

Cogent

$49.78

-0.495 (-0.98%)

07:05
02/21/19
02/21
07:05
02/21/19
07:05
Earnings
Cogent reports Q4 EPS 16c, consensus 18c »

Reports Q4 revenue $132M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 11

    Mar

  • 11

    Mar

  • 13

    Mar

MCRN

Milacron

$14.78

0.13 (0.89%)

07:05
02/21/19
02/21
07:05
02/21/19
07:05
Earnings
Milacron reports Q4 adjusted EPS 48c, consensus 37c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GIL

Gildan Activewear

$34.17

-0.17 (-0.50%)

07:05
02/21/19
02/21
07:05
02/21/19
07:05
Earnings
Gildan Activewear reports Q4 adj. EPS 43c, consensus 43c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.